On 9 September 2026, Kunming Dianchi Water Treatment Co., Ltd. (03768.HK) disclosed in an inside information announcement that shares held by controlling shareholder Kunming Dianchi Investment in the company remain under judicial freeze for three years (9 September 2026 to 8 September 2029) within RMB 123,530,242.28, following an assistance enforcement notice from the Panlong District People's Court; Kunming Dianchi Investment holds 37.79% of the company's domestic shares, all subject to pledges and/or freezes, and the company said its normal operations are unaffected.
On 9 September 2026, Guangdong ADWAY Construction (Group) Holdings Company Limited (06189.HK) announced the appointment of executive director Mr. Liu Zhenyu as chief executive officer with effect from 7 September 2026; Mr. Liu, aged 53, joined the group on 27 August 2026 and previously served in management roles at China Construction Second Engineering Bureau and several other companies, under a three-year service agreement with annual remuneration of RMB 80,000 (before tax).
On 9 September 2026, China Energy Engineering Corporation Limited (03996.HK) announced that its subsidiary Northwest Electric Power Design Institute had won the EPC contract for the Phase II of the Shaanxi Investment Zhaoshipan Power Plant (2×1000MW units) with a contract value of RMB 6.44 billion, covering two 1,000 MW ultra-supercritical coal-fired units and environmental facilities with a construction period of about 31 months; the contract has not yet been formally signed.
On 9 September 2026, HBM Holdings Limited (02142.HK) announced in a voluntary announcement that its partner Solstice Oncology had completed a USD 225 million Series A financing led by RA Capital Management and commenced operations; Solstice is advancing the second-generation Fc-enhanced anti-CTLA-4 antibody pruluzubartamab, with a Phase II study in MSS colon cancer expected to begin enrolment in early Q4 2026.
On 9 September 2026, Bilibili Inc. (09626.HK) announced the completion of its offering of convertible senior notes with an aggregate principal of USD 500 million due 2031 and the concurrent repurchase of approximately USD 100 million of Class Z ordinary shares; the hedging placement of borrowed shares and a secondary placement by a Tencent subsidiary were completed, while Tencent's subscription for an additional USD 200 million of notes and the related share repurchase remain subject to independent shareholders' approval at an EGM.
On 9 September 2026, ECI Technology Holdings Limited (08013.HK) announced the resignation of Mr. Lau Chi Yuen as company secretary to focus on other business arrangements, with Ms. Chan Suet Ngan appointed as his successor on the same day; Ms. Chan has over 23 years of experience in accounting, finance and company secretarial matters and is a member of CPA Australia and the HKICPA.
On 9 September 2026, Sun.King Technology Group Limited (00580.HK) announced that its subsidiaries Jiashan Sun.King, Sun.King Semiconductor and Wuhan Langde would establish a joint venture, Zhejiang Xuanju Microelectronics Co., Ltd. (registered capital RMB 20 million), focused on high-performance TPU AI chips and industry inference products, with the three subsidiaries contributing RMB 5 million in aggregate for a 25% interest; the participation of Chuangke and Jiashan Yuxin, connected with executive director Mr. Xiang Jie, makes the transaction a connected transaction subject to reporting and announcement but exempt from independent shareholders' approval.
On 9 September 2026, Anjoy Foods Group Co., Ltd. (02648.HK) announced that its wholly-owned Hong Kong subsidiary Hong Kong Anjoy Foods proposed to form a path company with Mutual Strategy Limited under 50.5%/49.5% shareholdings to invest in production and trading subsidiaries in Indonesia, with combined cash contributions of at least USD 74.25 million (including USD 37,496,250 from Anjoy) for producing and selling quick-frozen surimi products and other items; the investment does not constitute a connected transaction or major asset restructuring.
On 9 September 2026, Fountain Set (Holdings) Limited (00420.HK) announced that an indirect wholly-owned subsidiary proposed to acquire an 81% interest in a Vietnam textile company for a cash consideration of USD 27,945,000 (approximately HKD 219,089,000); the target's 100% equity was valued at approximately RMB 240,653,200 on an asset-based basis as of 30 April 2026, with consideration payable in three instalments; the acquisition constitutes a major transaction subject to shareholders' approval, with a circular expected by 31 October 2026.
On 9 September 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (01276.HK) announced that the NMPA had accepted the marketing authorisation application for Ruippotipeptide Injection, a GLP-1/GIP dual agonist developed by its subsidiary Fujian Shengdi, for glycaemic control in adults with type 2 diabetes; in the pivotal PRIME-2 study the 4 mg group achieved a mean HbA1c reduction of 2.78% with superiority over semaglutide 1 mg (p<0.0001), and cumulative R&D investment is approximately RMB 745.9 million.
On 9 September 2026, Shenwan Hongyuan Group Co., Ltd. (06806.HK) announced the completion of the issuance of the 2026 Tranche 2 perpetual subordinated bonds publicly offered to professional investors by its subsidiary Shenwan Hongyuan Securities, with an issue size of RMB 2 billion and a coupon rate of 1.89%, featuring a floating rate reset every five years; Shenwan Hongyuan Securities has been approved to publicly issue perpetual subordinated bonds of up to RMB 30 billion in aggregate face value, and the bonds are proposed to be listed on the Shenzhen Stock Exchange after registration.
On 9 September 2026, CSPC Pharmaceutical Group Limited (01093.HK) announced in a voluntary announcement that its rotigotine long-acting injection (SYH9087), a dopamine receptor agonist, had received NMPA approval for clinical trials in China, becoming the first subcutaneous rotigotine long-acting product cleared for clinical studies in China; the product is dosed once weekly without preparation, and the approved indication is Parkinson's disease.
On 9 September 2026, CSPC Pharmaceutical Group Limited (01093.HK) announced in a voluntary announcement that its goserelin extended-release injection (SYH9102), a GnRH receptor agonist, had received NMPA approval for clinical trials in China, becoming the world's first ready-to-use goserelin extended-release injection cleared for clinical studies; the product is dosed once monthly without preparation, showed superior castration rates and maintenance versus marketed microsphere formulations in preclinical studies, and the approved indication is solid tumours.
On 9 September 2026, Sunshine Oilsands Ltd. (02012.HK) issued a supplementary announcement stating that its AI computing power joint venture with multiple partners had completed industrial and commercial registration and been formally incorporated as Dineng Zhisuan AI (Qinhuangdao Beidaihe District) Co., Ltd. (originally proposed as Dineng Zhisuan AI (Beidaihe) Co., Ltd.); joint venture partner Jiangsu Zhongke Supply Chain Management Co., Ltd. was renamed Zhongke (Nanjing) Investment Holdings Co., Ltd., and the project's design plan has been finalised with approval procedures underway.
On 9 September 2026, EPS HEALTH TECH (03860.HK) announced that controlling shareholder EPS HD agreed to sell up to 130 million shares (22.32%) to Wisdoms Group in two tranches at HKD 0.63 per share.
On 9 September 2026, HAIDILAO (06862.HK) announced that controlling shareholder group member SP NP sold 259 million shares at HKD 10.62 each via a block trade on 8 September; following the disposal, the controlling shareholders hold approximately 45.49% and control remains unchanged.
